Alicia C Smart

Dr. Alicia C Smart

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ASAlicia C Smart
Alicia C Smart
KLKevin X. Liu
Kevin X. Liu
JDJason D. Domogauer
Jason D. Domogauer
CRCarlos Rodriguez-Russo
Carlos Rodriguez-Russo
BJBrianna Jones
Brianna Jones
ARAndrea L. Russo
Andrea L. Russo

6 February 2024 in Advances in Radiation Oncology
Verified
Journal Article
Open access
BGBeck Gold
Beck Gold
PLPin-Ji Lei
Pin-Ji Lei
SKSophia C. Kamran
Sophia C. Kamran
DHDaphne A. Haas-Kogan
Daphne A. Haas-Kogan
IFIdalid Franco
Idalid Franco
JWJennifer Y. Wo
Jennifer Y. Wo
Sexual and gender minority (SGM) individuals have an increased risk of poor health outcomes, in part due to knowledge and training gaps in health care education. This study sought to evaluate the knowledge, attitudes, and practice behaviors of various health care role groups within radiation oncology toward SGM patients. A 38-item web-based survey was emailed to 1045 staff across 2 large radiation oncology departments. The survey assessed demographics, attitudes, knowledge, and practice behaviors. χ2 tests were performed to explore differences in survey responses by age, political affiliation, religious identity, year since graduation, and role groups. One-way analysis of variance tests were conducted to determine differences between respondents’ confidence in knowledge and performance on the knowledge section of the survey. Thematic analysis was applied to the open discussion section. Of the 223 respondents, 103 clinicians (physicians/advanced practice providers/nurses) and 120 nonclinicians (administrative staff, medical assistants, and other nonmedical staff) participated in the survey (21.3% response rate): 72.6% answered the knowledge questions; 93.5% stated they were comfortable treating sexual minorities, or lesbian, gay, bisexual, and queer + patients; 88% indicated comfort in treating transgender patients; 36.6% stated they were confident in their knowledge of the health needs of transgender patients; and 50.3% expressed confidence in treating lesbian, gay, bisexual, and queer + patients. Fewer nonclinicians than clinicians thought that gender identity, sexual orientation, and sex assigned at birth were important to provide the best care (P < .05). The open comments section identified key themes, including the belief that current educational tools are not helpful, desire for more educational formats (lectures, case-based learning, seminars), and an overall interest in SGM health education. Most staff feel comfortable in treating SGM patients but are less confident in the distinct needs of this population. Knowledge gaps persist for both clinicians and nonclinicians, indicating a need for further training specific to oncology care.

1 June 2024 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
ASAlicia C Smart
Alicia C Smart
MYMichael J. Yunes
Michael J. Yunes
KWKaren M. Winkfield
Karen M. Winkfield
This Viewpoint calls for health care systems, oncologists, and staff to prioritize and adopt policies that are inclusive and respectful of transgender patients with cancer.

7 September 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
AMArian Mansur
Arian Mansur
AKAbigail M. Kempf
Abigail M. Kempf
DBDanielle S. Bitterman
Danielle S. Bitterman
CPChirayu G. Patel
Chirayu G. Patel
MDM Aiven Dyer
M Aiven Dyer
ASAlicia C Smart
Alicia C Smart
Introduction: Approximately 1.6 million people in the US identify as transgender, many of whom undergo gender-affirming medical or surgical therapies. While transgender individuals are diagnosed with cancer at similar rates as those who are cisgender, the impacts of radiation therapy on outcomes of gender-affirming care in transgender, nonbinary, and gender-expansive people with cancer are understudied. We report on the experiences and outcomes of transgender and gender-expansive patients receiving radiation therapy for cancer treatment.Methods: This study is a multi-institutional retrospective review of patients evaluated from 2005-2019 identified as transgender or gender-expansive in the medical record and treated with radiation therapy.Results: We identified 23 patients who received radiation to 32 sites, including 12 (38%) to the brain, head, or neck, 8 (25%) to the thorax, and 7 (22%) to the pelvis. Seventeen patients (74%) received gender-affirming hormone therapy and 13 patients (57%) underwent gender-affirming surgery. Four patients had pelvic radiation before or after gender-affirming pelvic surgery, including two trans women who had pelvic radiation after vaginoplasty. Four patients had radiation to the chest or thorax and gender-affirming chest or breast surgery, including two trans men with breast cancer. Two pediatric patients developed hypopituitarism and hypogonadism secondary to radiation therapy and, as adults, changed their hormone replacement therapy to affirm their transgender identities.Discussion: Transgender people with cancer undergo radiation therapy for a wide range of cancers. Understanding their prior gender-affirming medical or surgical treatments and future gender affirmation goals may identify important considerations for their oncologic care.

1 August 2025 in Cancer Medicine
Verified
Journal Article
Open access
SFSayeh Fattahi
Sayeh Fattahi
MCMing‐Hui Chen
Ming‐Hui Chen
JWJing Wu
Jing Wu
ASAlicia C Smart
Alicia C Smart
ADAnthony V DAmico
Anthony V DAmico
Background: A low serum testosterone can prolong the time needed for PSA to exceed normal and prompt a work‐up to rule out prostate cancer (PC), delaying diagnosis. We evaluated PC aggressiveness at diagnosis and PC‐specific and all‐cause mortality (PCSM, ACM)‐risk within comorbidity subgroups in patients with low versus normal testosterone. Methods: Between 2005 and 2015, 350 PSA‐screened patients with tumor (T) category1c‐4N0M0 unfavorable‐risk PC were enrolled in a randomized trial and comprised the study cohort. Fine and Gray and Cox multivariable regression analyses were used to evaluate PCSM and ACM risk, respectively, adjusting for age, known PC prognostic factors, randomized treatment arm, and the time‐dependent use of salvage androgen deprivation therapy. An interaction term between the Adult Comorbidity Evaluation‐27 defined comorbidity and low versus normal testosterone was included in the models to enable an assessment of PCSM and ACM risk within comorbidity subgroups in patients with low versus normal testosterone levels at randomization. Results: After a median follow up of 10.20 years, 89 of 350 patients died (25.43%) with 42 of 89 deaths (47.19%) from PC. In patients with no or minimal but not moderate to severe comorbidity, a significant association was observed between low compared to normal testosterone level at randomization and increased PCSM (AHR: 2.70 [95% CI: 1.27, 5.76], p = 0.01) and ACM risk (AHR: 1.90 [95% CI: 1.11, 3.26], p = 0.02). Conclusion: Unlike PSA, multiparametric MRI (mpMRI) images are not influenced by the serum testosterone level; therefore, evaluating whether PCSM can be reduced by incorporating mpMRI into PC‐screening in otherwise healthy men or transgender women with a low serum testosterone level should be considered. Trial Registration: The statisical code used to derive the results from the interaction model for this post randomization analysis can be found in the Supporting Information.

Verified
Journal Article
Open access
PDF file
SFSayeh Fattahi
Sayeh Fattahi
Yetkin TuaçYetkin Tuaç
Yetkin Tuaç
OAOkan Argun
Okan Argun
BTBryce James Thomsen
Bryce James Thomsen
ASAlicia C Smart
Alicia C Smart
MSMutlay Sayan
Mutlay Sayan
Background/Objectives: Cribriform architecture is an adverse Gleason pattern 4 morphology associated with aggressive prostate cancer outcomes. Tertiary Gleason pattern 5, even as a minor component, may also identify tumors with higher-grade biology not fully captured by conventional Grade Group assignment. We examined whether cribriform architecture is associated with tertiary Gleason pattern 5 in patients undergoing radical prostatectomy. Methods: We performed a retrospective cross-sectional study of radical prostatectomy specimens from patients with prostate adenocarcinoma who underwent radical prostatectomy and had available clinicopathologic data. A centralized pathology review of digitized radical prostatectomy slides was used to assess cribriform architecture. Tertiary Gleason pattern 5 status was obtained from original pathology reports. Multivariable logistic regression was used to evaluate the association between cribriform architecture and tertiary Gleason pattern 5 after adjustment for age, preoperative prostate-specific antigen level, prostatectomy Gleason score, pathologic tumor stage, and margin status. Results: Among 303 patients, 47 (15.5%) had tertiary Gleason pattern 5. Cribriform architecture was more common in tumors with tertiary Gleason pattern 5 than in those without (70% vs. 21%; p < 0.001). On multivariable analysis, cribriform architecture remained independently associated with tertiary Gleason pattern 5 (adjusted odds ratio of 9.46; 95% confidence interval of 4.49–21.0; p < 0.001). The model demonstrated good discrimination, with an area under the receiver operating characteristic curve of 0.80. Conclusions: Cribriform architecture was strongly associated with tertiary Gleason pattern 5. These findings suggest that cribriform-positive tumors may be more likely to harbor minor high-grade pattern 5 components.